摘要
卡瑞利珠单抗是一种免疫治疗药物,肿瘤患者在临床使用过程中发生反应性皮肤毛细血管增生症(reactive cutaneous capillary endothelial proliferation,RCCEP)概率较高,生活质量和样貌特征受到影响,产生恐慌心理,治疗积极性降低。该文从RCCEP的临床表现、分级标准、发病机制等多角度进行阐述,综述了RCCEP预后治疗的各类方案,以提高患者使用卡瑞利珠单抗的依从性,为临床治疗提供参考。
Camrelizumab is an immunotherapy drug,and the incidence of reactive cutaneous capillary endothelial proliferation(RCCEP)is high in tumor patients during clinical use,which would affect the quality of life and appearance characteristics of patients,make patients panic and decrease their treatment enthusiasm.In this paper,the clinical manifestations,grading standards,pathogenesis and other aspects of RCCEP were expounded,and various schemes of prognosis treatment for RCCEP were summarized,so as to improve the compliance of patients with camrelizumab and provide reference for clinical treatment.
作者
张金铭
韩冰
崔萌纳
梁瑜
李晓
仓怀芹
全香花
ZHANG Jinming;HAN Bing;CUI Mengna;LIANG Yu;LI Xiao;CANG Huaiqin;QUAN Xianghua(Department of Pharmacy,Affiliated Hospital of Qingdao University,Shandong Qingdao 266003,China;School of Pharmacy,Yanbian University,Jilin Yanji 133002,China)
出处
《中国医院药学杂志》
CAS
北大核心
2023年第19期2226-2230,共5页
Chinese Journal of Hospital Pharmacy
